Stifel Initiates Coverage On Pyxis Oncology with Buy Rating, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Bradley Canino has initiated coverage on Pyxis Oncology (NASDAQ:PYXS) with a Buy rating and a price target of $10.
August 08, 2024 | 10:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Bradley Canino has initiated coverage on Pyxis Oncology with a Buy rating and a price target of $10.
The initiation of coverage with a Buy rating and a price target of $10 by a reputable analyst is likely to positively impact the stock price of Pyxis Oncology in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100